Recordati to Acquire Sanofi’s Enjaymo, Enhancing its Rare Diseases Portfolio
Shots:
- Recordati has signed an agreement with Sanofi to secure worldwide rights of Enjaymo (sutimlimab), developed for the treatment of cold agglutinin disease (CAD)
- As per the agreement, Sanofi will get $825M upfront and additional ~$250M commercial milestones if net sales achieved certain thresholds at or above the top end of peak year sales expectations. The deal is anticipated to conclude by the YE’24, pending regulatory approvals
- Enjaymo (IV) is a humanized mAb approved to treat hemolysis in adults with CAD across major markets. It works by targeting C1s in the classical complement pathway to inhibit complement cascade activation & C1 activated hemolysis, preventing abnormal destruction of healthy RBCs
Ref: Recordati | Image: Recordati
Related News: Sanofi’s Enjaymo (sutimlimab) Receives EC’s Approval for Hemolytic Anemia in Adult Patients with Cold Agglutinin Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
